Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Depression
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 07 Feb 2017 study is completed in 2011 and sponsor is changed after study completion,hence BlackThorn Therapeutics, Inc. is not added in association.
- 27 Jun 2016 Results published in the Drug Metabolism and Disposition
- 14 Dec 2014 Dose of LY2940094 is changed for every cohort as cohort 1: 100mg to 40mg, cohort 2: 2-800mg to 10mg, cohort 3: 2-800mg to 4mg, cohort 4: 2-800mg to 20mg as per ClinicalTrial.gov record.